At what enterprise value was VIVALTO VIE acquired in 2020?

During the acquisition of VIVALTO VIE by AMUNDI PRIVATE EQUITY / SOCIETE GENERALE CAPITAL PARTENAIRES in 2020, the company was valued at an estimated revenue multiple of below 5x. The transaction's Enterprise Value is estimated to be in the range of 100M - 350M EUR. By registering for free, you get access to complete and exact transaction details including enterprise value, revenue, and EBITDA. Additionally, our database shows that the Healthcare & Pharma industry currently tracks an average EBITDA multiple of 14.8x, providing a valuable benchmark for this transaction.

What was the EV/EBITDA of VIVALTO VIE when it was acquired by AMUNDI PRIVATE EQUITY / SOCIETE GENERALE CAPITAL PARTENAIRES?

The estimated EV/EBITDA multiple for VIVALTO VIE is in the range of 10x - 18x. For comparison, the Healthcare & Pharma sector currently shows an average EBITDA multiple of 14.8x. Join our community for free to access full valuation data and industry trends.

What was the revenue of VIVALTO VIE at the time of the deal?

The revenue of VIVALTO VIE at the time of the deal is estimated to be in the range of 50M - 100M EUR. Register for free to access the full transaction report and exact valuation multiples.

What was the EBITDA of VIVALTO VIE during the acquisition?

VIVALTO VIE's EBITDA is estimated to be in the range of 5M - 25M EUR. Join our community for free to access complete and exact deal data.

What is Enterprise Value (EV)?

Enterprise Value (EV) is a measure of a company's total value, often used as a more comprehensive alternative to equity market capitalization. EV includes in its calculation the market capitalization of a company but also short-term and long-term debt as well as any cash on the company's balance sheet.

What is the EV/EBITDA multiple and why is it used?

The EV/EBITDA multiple is a financial ratio that compares a company's Enterprise Value (EV) to its Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA). It is widely used in M&A and valuation because it allows for comparisons between companies with different capital structures and provides a clear view of operational profitability.

How is the data for the VIVALTO VIE acquisition sourced and is it reliable?

Mynth data is contributed by a professional community of M&A and Private Equity experts. Each transaction, including the VIVALTO VIE deal, is systematically cross-verified by our team using private deal documents and official sources. You can also find the official press release for this transaction here: https://capitalfinance.lesechos.fr/deals/lbo/amundi-pef-valorise-vivalto-vie-230-m-1171512

← DATABASE

Home Database Healthcare & PharmaVIVALTO VIE

02/2020

VIVALTO VIE acquired by AMUNDI PRIVATE EQUITY & SOCIETE GENERALE CAPITAL PARTENAIRES

FRANCE Health Providers / Healthcare Facilities / Nursing Homes EV 100M - 350M EUR

Context

Amundi PEF acquired a minority but leading stake in Vivalto Vie from Azulis Capital, which had been the group's largest shareholder since 2015 with approximately 35% of the capital. The sale process was mandated to Natixis Partners and Azulis Capital exited at a multiple exceeding 3x its initial investment. Société Générale Capital Partenaires entered the shareholder structure alongside Amundi PEF, while BNP Paribas Développement and Socadif retained small existing positions. Operational control of the group remains with Vivalto Partners. The transaction was financed through a unitranche facility provided by Ardian and a PIK instrument from CIC Private Debt and BNP Paribas PI, totalling €100 million, complemented by an €80 million capex line to support the group's development pipeline. Simultaneously with the LBO, Vivalto Vie completed the acquisition of Solimar in Spain, marking its first international expansion.

VIVALTO VIE, which reported an EBITDA margin of LOGIN in 2019, is valued in this transaction at an EV/EBITDA multiple of LOGIN, representing a LOGIN to the average currently observed in the Healthcare & Pharma sector (14.8x).

Note that this data is based on contribution from our growing community, composed of M&A and Private Equity professionals, and has been verified by our team to ensure its accuracy.

-> Deep-dive in Healthcare & Pharma market trends

Target

Vivalto Vie is a French nursing home operator historically concentrated in the north-west of France, managing numerous facilities . A distinctive feature of Vivalto Vie is its property ownership model — the group owns its real estate assets, which significantly enhances its balance sheet value but also adds operational complexity in the context of a PE transaction. The group has embarked on a European expansion strategy, with Spain as its first international market.

Ent. Value

Equity Value

Multiples

EV / Revenue

EV / EBITDA

EV / EBIT

Historical Financials (EUR)

Year

Rev

EBITDA

EBIT

2019

2018

Other operations with VIVALTO VIE

List of similar M&A transactions (Date, Acquirer, Target, Country, Sector, Deal Context)
Date	Acquirer	Target	Country	Sector	Deal Context
02/2020	VIVALTO VIE	SOLIMAR	SPAIN	Health Providers	Vivalto Vie acquired 100% of Solimar, a Valencia-based nursing home operator, marking the group's first international expansion outside France. The transaction was executed simultaneously with the closing of the Amundi PEF-led LBO of Vivalto Vie and represents the first building block of the group's Spanish platform, which targets a pipeline of approximately 1,000 additional beds through a combination of further acquisitions and greenfield development projects.

REFERENCES

Valuation range: EV 100M - 350M EUR

Revenue range: 50M - 100M EUR

EBITDA range: 5M - 25M EUR

Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of VIVALTO VIE by AMUNDI PRIVATE EQUITY / SOCIETE GENERALE CAPITAL PARTENAIRES are reserved for mynth community members. Register for free to unlock full data.

Authors: verified mynth contributor (mynth data is contributed by M&A / PE professionals and systematically cross-verified with private deal documents and official press releases).

Acquirer: amundi private equity / societe generale capital partenaires